The regression coefficients affecting the pharmacokinetic parameters of the breakpoints of antimicrobial agents (ie, empiric breakpoints) obtained retrospectively from clinical trial data were considered, and the phan'nacokinetic parameters that were thought to strongly correlate to the empiric breakpoints were selected. The regression coefficients of the selected pharmacokinetic parameters were estimated, based on the categoric regression analysis. Estimated regression coefficients were rounded, and breakpoints were constructed using these rounded values. The breakpoint for complicated cystitis was deterhfined, and it was decided that to obtain the breakpoint of complicated pyelonephritis, one tube (ie, one-half value) would be subtracted from the breakpoint of complicated cystitis, as calculated using the formula.
INTRODUCTION
The following 3 factors are taken into consideration when selecting an antimicrobial agent to treat an infectious disease: the MIC against the causative bacteria, the drug concentration in the infectious focus when a standard dosage of the drug is administered, and the patient's resistance to infections (immunologic potency). Once the MICs of candidate antimicrobial agents are known, we can decide on a suitable antimicrobial agent, based on the patient's status and the pharmacokinetics of the agent. Currently, in medical therapies for urinary tract infections, the antimicrobial agent has been selected on the basis of a vague assumption of its efficacy derived from the general urinary system distribution of the agent. The breakpoint MIC is a simple borderline value for a more scientific selection of a drug in actual clinical practice, where a quick judgment is demanded. Generally speaking, the breakpoint MIC is defined as the MIC for which a clinical effect is expected at a high rate (> 80%) for bacteria against which the MIC of a given drug is lower than the breakpoint. In other words, a drug with a higher breakpoint MIC would have a wider range of MICs that could be expected to show efficacy.
The Study Group of the Japan Society of Chemotherapy for Measuring Sensitivity of Antimicrobial Agents (for urinary tract infections; chairman: Sadao Kamidono) has constructed a formula to calculate break- Received Dec. 4, 1997; accepted for publication in revised form Jan. 21, 1998 . *Correspondence and requests for reprints to: Department of Urology, Kobe University School of Medicine, Japan. points of antimicrobial agents for complicated urinary tract infections. The breakpoint of each antimicrobial agent was calculated on the basis of the outcomes of comparative clinical trials (we refer to this as the empiric breakpoint hereafter).Then this empiric breakpoint was characterized by pharmacokinetic parameters. Finally, a formula was derived to estimate the empiric breakpoint by combining typical parameters (from here on, the breakpoint estimated by the formula is referred to as the predicted breakpoint).
We reported the method for setting up the empiric breakpoints in our first report. 1 In this paper, we present the predicted breakpoints of antimicrobial agents for complicated urinary tract infections on the basis of the formula derived theoretically, using statistical techniques together with discussion on various problems arising in setting the formula.
MATERIALS AND PHARMACOKINETIC PARAMETERS

Materials
Based on the comparative clinical trials of oral and parenteral intravenous antimicrobial agents for complicated urinary tract infections, whose results were published in the Journal of the Japan Society of Chemotherapy in the past 10 years, 48 antimicrobial agents were selected. There were 8635 eligible cases for analysis. For details of the respective drugs, refer to our first report.
Pharmacokinetic parameters
Seven pharmacokinetic parameters obtained in phase I clinical trials of the 48 antimicrobial agents with the sin-1341-321X/98/O402-OO97/US$3.00 9 JSC/CLJ 1998 gle administration of ordinary dosages were used. The mean values for the agents were adopted as their pharmacokinetic parameters.The 7 pharmacokinetic parameters are as follows: maximum blood concentration (Cmax), half-life (T 1/2), area under the curve (AUC), protein binding rate (Protein), maximum urinary concentration (Umax), 1-day cumulative urinary excretion (UV), and Umax/Cma x (Utr).
Statistical analysis
Selection of pharmacokinetic parameters. Correlations among the pharmacokinetic parameters and regressions of empiric breakpoints 1 on the pharmacokinetic parameters were examined. Then the parameters with a relatively strong association with the empiric breakpoint were selected.
Derivation of the formula to calculate empiric breakpoints. Based on categoric regression analysis (Hayashi's quantification method), 2 regression coefficients of the above pharmacokinetic parameters were estimated. Estimated regression coefficients were rounded and breakpoints were constructed using these rounded values. Then, we examined performances of the breakpoints of antimicrobial agents individually.
RESULTS OF ANALYSES
Formula to calculate breakpoints of antimicrobial agents for complicated cystitis
Selection of pharmacokinetic parameters. To select pharmacokinetic parameters that were relevant to the empiric breakpoints of antimicrobial agents, correlation coefficients of the pharmacokinetic parameters with the empiric breakpoints were determined. Those that showed strong correlation were explored. In this analysis, 6 drugs (cefsulodin, cefclidin, sulbactam/cefoperazone, cefmetazole, cefminox, and arbekacin) were excluded from the 48 drugs due to reasons such as: small numbers of cases whose baseline MIC was measured, all the eradication rates with respect to the baseline MIC were lower than 80% and empiric breakpoints (for complicated cystitis) could not be established, and withdrawal of the NDA (new drug application), Moreover, 11 drugs among the 42 drugs (Table 1) were judged ineligible for evaluation because some of the pharmacokinetic parameters were missing. Among the 7 parameters, Protein was excluded because the protein values were available only for 24 drugs. Consequently, 31 drugs and 6 parameters remained to be examined. A correlation matrix (Table 2) between these pharmacokinetic parameters, MICs0 in the clinical trials, daily dose, and the empiric breakpoints were examined.Then, the pharmacokinetic parameters related to concentration (ie, Cma x, AUC, Urea x, UV, and Utr) and the empiric breakpoints, were subjected to log transformation.
All the correlation coefficients among the following 5 parameters, that is, Cmax, AUC, Umax, UV, and daily dose, were higher than 0.7, indicating a strong relationship among them. Urea x was selected as a representative parameter of the 5, because Urea x showed the highest correlation coefficient with the empiric breakpoint (correlation coefficient: 0.582, and contribution ratio: 33.9%). In addition to Urea ~, T1/2 and MICs0 were selected as parameters to be examined because T1/2 was not correlated with the above 5 parameters and MICs0 was a direct parameter for antimicrobial activity.
Formula to calculate breakpoints. First, to construct a calculation formula for breakpoints of antimicrobial agents, categoric regression analysis was performed using 4 parameters, 2 pharmacokinetic parameters selected above (Umax, and T1/2), MICs0 and drug profile, as explanatory variables, and the empiric breakpoint as response. Umax, T1/2, and MICs0 were categorized. Namely, T1/2 (hour) was divided into 3 categories (< 1, < 2, >_ 2 ), Uma x (]Ag/mL) into 5 (< 100, <3 00, < 1000, < 3000, _> 3000) and MICs0 (J/g/mL) into 2 (< 50, _> 50), respectively. Two types of classification with drugs (drug profile), type A and type B, were established. Type A consisted of 2 divisions, 1 for parenteral drugs and the other for orally administered drugs.Type B consisted of 3 divisions, 1 each for parenteral drugs, oral quinolones and oral cephem drugs. Partial correlation coefficient and range were high in Uma x and in the drug profile for both classification, type A and type B, and it was shown that these 2 parameters particularly contributed to empiric breakpoints (Table 3 ). In the examination with respect to the sign and size of the Urea x coefficient, the greater the Uma x was, the higher the estimated empiric breakpoint became. With respect to the drug profile, empiric breakpoints tended to be low for oral drugs and high for parenteral drugs.
Next, the formula to predict an empiric breakpoint for each drug was obtained through examination of the estimated regression coefficients in the categoric regression analysis. To simplify this prediction formula, the estimated regression coefficients were replaced with their rounded values, the estimated regression coefficients were exponentially transformed, and the transformed coefficients were replaced with their rounded values in 0.5 increments (Table 4) . For example, 0.5 was assigned as a rounded value to the regression coefficient of the category corresponding to "< 1" of 7"1/2 in type A, which was actually 0.711. The rounded value for MIC80 was 1.0 in both categories, irrespective of type A or B and, consequently, it did not contribute to the prediction formula in type A or B.Therefore, the MIC80 was excluded from the parameters selected for determination of a prediction formula.
Predicted breakpoints of the respective antimicrobial agents were evaluated using the rounded values. The results are shown in column 4 (type A) and column 6 (type B) of Table 5 . For example, the method to predict
